Improving selectivity of dopamine D3 receptor ligands

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Neuroscience

Background:

• The human dopamine D3 receptor (hD3R) is a key target for neurological disorders.
• The previously developed ligand BP 897 showed promise but lacked selectivity.
• Poor selectivity for adrenergic receptors hindered BP 897's clinical development.

Purpose of the Study:

• To develop novel ligands with enhanced selectivity for the hD3R.
• To overcome the limitations of BP 897 by improving adrenergic receptor selectivity.
• To identify potent and selective hD3R ligands for potential therapeutic applications.

Main Methods:

• Lead optimization of existing hD3R ligands.
• Structure-activity relationship studies to guide ligand design.
• In vitro assays to assess receptor binding affinity and selectivity.

Main Results:

• Successful lead optimization yielded novel hD3R ligands.
• Achieved subnanomolar potency for the human dopamine D3 receptor.
• Demonstrated good selectivity for hD3R over the closely related human dopamine D2 and human adrenergic alpha-1 receptors.

Conclusions:

• The developed ligands represent a significant advancement in hD3R-targeted drug discovery.
• These compounds exhibit improved selectivity profiles, addressing previous development hurdles.
• The findings support further investigation of these ligands for therapeutic potential in conditions involving the hD3R.